Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.

Renata FerrarottoRobert CardnellShirley Y SuLixia DiaoA Karina EterovicVictor PrietoWilliam H MorrissonJing WangMerrill S KiesBonnie S GlissonLauren Averett ByersDiana Bell

Published in: Head & neck (2018)

Based on PARP1 overexpression, DNA-damage repair gene mutations, platinum sensitivity, and activity of olaparib in a Merkel cell carcinoma line, clinical trials with PARP inhibitors are warranted in Merkel cell carcinoma.

Keyphrases

dna damage
dna repair
clinical trial
oxidative stress
cell proliferation
transcription factor
randomized controlled trial
phase ii
phase iii
double blind